Zai Lab (ZLAB) announced that China’s National Medical Products Administration, NMPA, has accepted the New Drug Application, NDA, for KarXT for the treatment of schizophrenia in adults. “There are more than 8 million patients living with schizophrenia in China who face significant unmet needs due to the limited efficacy and undesirable side effects of current treatment options,” said Dr. Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. “In clinical trials, KarXT demonstrated statistically significant reductions of schizophrenia symptoms along with a tolerable safety profile. If approved, KarXT has the potential to redefine the treatment landscape.”
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB:
- Zai Lab announces results from innovaTV 301 study
- Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement
- Zai Lab enters Tmalin license agreement with MediLink Therapeutics
- Morning Movers: Intel climbs following retirement of CEO Pat Gelsinger
- Zai Lab, Novocure announce PANOVA-3 trial met primary endpoint